drugset / Trial / NCT01135212
The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension
Phase 3
Completed
290 enrolled
Boryung Pharmaceutical Co., Ltd
Daegu Catholic University Medical Center · collabDong-A medical center · collabGyeongsang National University Hospital · collabInje University · collabKeimyung University · collabKosin University Gospel Hospital · collabKyungpook National University Hospital · collabPusan National University Hospital · collabPusan National University Yangsan Hospital · collabUlsan University Hospital · collabYeungnam University Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this clinical study is to evaluate and compare the efficacy and safety of Fimasartan (60mg / 120mg) with Candesartan(8mg) in patients with mild to moderate hypertension.
Timeline
- Start
- 2010-04
- Primary completion
- 2011-04
- Completion
- 2011-05
Publications
- Lee JH, Yang DH, Hwang JY, Hur SH, Cha TJ, Kim KS, Kim MH, Chun KJ, Cha GS, Hong GR, Lee SG, Kim DS, Kim DI, Chae SC. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. Clin Ther. 2016 Jun;38(6):1485-1497. doi: 10.1016/j.clinthera.2016.04.005. Epub 2016 May 6.
- Fimasartan. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):249-52. doi: 10.2165/11533640-000000000-00000.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Candesartan cilexetil | Unknown | 8 mg | Oral |
| Comparator | Fimasartan | Small molecule | 60 mg | Oral |
| Comparator | Fimasartan | Small molecule | 120 mg | Oral |